Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 60

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 60
---
, subsequently confirmed by delivery of a written opinion dated November 14, 2025, to the effect that, as of such date
and based upon and subject to the various assumptions made, and the qualifications and limitations upon

33

the review undertaken by Leerink Partners in preparing its opinion, the cash consideration proposed to be paid to the Shareholders (other than holders of Excluded Shares) pursuant to the terms of
the Arrangement was fair, from a financial point of view, to such holders. For a detailed discussion of the opinion of Leerink Partners, please see Item — under the heading “The Arrangement—Opinion of Leerink Partners” The written opinion of Leerink Partners is attached to this Circular and Proxy Statement as Annex B. Representatives of Stikeman then discussed
the fiduciary duties of directors in connection with evaluating the Company’s strategic alternatives and discussed the material terms in the Agreement and the CVR Agreement with the members of the Transaction Committee and the other directors
of the Company. Following additional discussion and consideration of the Agreement and the CVR Agreement (including the factors described below under the heading “Reasons for the Arrangement”), the Transaction Committee
unanimously and after careful consideration, including thorough consideration of (i) the extent of the strategic review process and the subsequent negotiations with the Purchaser and the Parent and the Transaction Committee’s oversight
thereof, (ii) the cash amount expected to be received by the Shareholders and the certainty of value associated therewith, (iii) the potential additional value that may be provided through the CVR Agreement, (iv) the reasonableness of
the transaction fee to the Purchaser under the Arrangement, (v) the Company’s prospects in continuing its business on a standalone basis, (vi) the expected return to securityholders of the Company if the Company were alternatively
liquidated, (vii) the level of transaction certainty associated with the Arrangement, including as a result of limited conditionality and no required regulatory approvals, (viii) the “deal protection” provisions of the
Agreement, (ix) the Company’s ability to respond to unsolicited superior proposals under the terms of the Agreement and the ability for the Board to change its recommendation in certain circumstances, (x) the support of the
Company’s directors and officers, (xi) the Company’s ability to endeavour to monetize its programs and intellectual property in the interim period, (xii) the required shareholder and court approvals required to complete the
Arr